NCT07012486 Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
| NCT ID | NCT07012486 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Shanghai Zhongshan Hospital |
| Condition | Androgenetic Alopecia (AGA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-06 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2025-06 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is: • Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA. Participants will: * Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.
Eligibility Criteria
Inclusion Criteria: * Clinically diagnosed with androgenetic alopecia (AGA) * No pregnancy plans within the next 6 months Exclusion Criteria: * Patients who received systemic medications for hair loss within the past 2 months * Use of topical medication for hair loss within the past 2 weeks * Pregnancy or lactation * Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.
Contact & Investigator
Jingjing JIANG, MD, PhD
PRINCIPAL INVESTIGATOR
Fudan University
Frequently Asked Questions
Who can join the NCT07012486 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Androgenetic Alopecia (AGA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07012486 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07012486 currently recruiting?
Yes, NCT07012486 is actively recruiting participants. Contact the research team at gao.lujuan@zs-hospital.sh.cn for enrollment information.
Where is the NCT07012486 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07012486 clinical trial?
NCT07012486 is sponsored by Shanghai Zhongshan Hospital. The principal investigator is Jingjing JIANG, MD, PhD at Fudan University. The trial plans to enroll 30 participants.